首页> 外文期刊>International journal of pediatric endocrinology >Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
【24h】

Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit

机译:生长激素显着增加特发性矮小儿童的成人身高:亚组和获益的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Children with Idiopathic Short Stature do not attain a normal adult height. The improvement of adult height with treatment with recombinant human growth hormone (rhGH), at doses of 0.16 to 0.28 mg/kg/week is modest, usually less that 4 cm, and they remain short as adults. The benefit obtained seems dose dependent and benefits of 7.0 to 8.0 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week, but the number of studies is limited. The topic has remained controversial. Objective: The objective was to conduct a retrospective analysis of our experience with 123 children with ISS treated with 0.32 ± 0.03 mg/kg/week of rhGH, with the aim of comparing the different subgroups of non-familial short stature, familial short stature, normal puberty, and delayed puberty and to assess the benefit by comparison with 305 untreated historical controls, from nine different randomized and nonrandomized controlled studies. Results: Eighty eight of our children (68 males and 20 females) attained an adult height or near adult height of-0.71 SDS (0.74 SD) (95% CI, -0.87 to -0.55) with a benefit over untreated controls of 9.5 cm (7.4 to 11.6 cm) for males and 8.6 cm (6.7 to 10.5 cm) for females. In the analysis of the subgroups, the adult height and adult height gain of children with non-familial short stature were significantly higher than of familial short stature. No difference was found in the cohorts with normal or delayed puberty in any of the subgroups, except between the non-familial short stature and familial short stature puberty cohorts. This has implications for the interpretation of the benefit of treatment in studies where the number of children with familial short stature in the controls or treated subjects is not known. The treatment was safe. There were no significant adverse events. The IGF-1 values were essentially within the levels expected for the stages of puberty. Conclusion: Our experience was quite positive with normalization of the heights and growth of the children during childhood and the attainment of normal adult heights, the main two aims of treatment.
机译:背景:患有特发性矮小的儿童无法达到正常的成人身高。剂量为0.16至0.28 mg / kg /周的重组人生长激素(rhGH)治疗可以使成年人身高有所改善,通常不超过4厘米,并且与成年人一样短。所获得的益处似乎是剂量依赖性的,据报道,剂量为0.32至0.4 mg / kg /周时,获益为7.0至8.0 cm,但研究数量有限。这个话题仍然有争议。目的:回顾性分析我们对123名接受0.32±0.03 mg / kg /周rhGH治疗的ISS儿童的经验,目的是比较非家族性矮小,家族性矮小,正常青春期和青春期延迟,并通过与305个未经治疗的历史对照进行比较来评估获益,这些对照来自9个不同的随机和非随机对照研究。结果:我们的88名儿童(68名男性和20名女性)达到了-0.71 SDS(0.74 SD)的成人身高或接近成人身高(95%CI,-0.87至-0.55),比未经治疗的9.5 cm对照者受益男性为(7.4至11.6厘米),女性为8.6厘米(6.7至10.5厘米)。在亚组分析中,非家族性矮小儿童的成人身高和成年身高显着高于家族性矮小儿童。除了非家族性矮身材和家族性矮身材青春期队列外,在任何亚组中,青春期正常或延迟的队列均无差异。这对于在对照或接受治疗的受试者中患有家族性矮小儿童的儿童数量未知的研究中对治疗益处的解释具有意义。治疗是安全的。没有明显的不良事件。 IGF-1值基本上在青春期阶段的预期水平之内。结论:我们的经验对儿童的身高和成长正常化以及达到正常的成人身高是非常积极的,这是治疗的主要两个目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号